KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK, Sept. 6, 2022

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline: October 4, 2022
No obligation or cost to you.

Learn more about your recoverable losses in KRBP:
https://www.kleinstocklaw.com/pslra-1/kiromic-biopharma-inc-loss-submission-form?id=31349&from=4

Kiromic BioPharma, Inc. NEWS - KRBP NEWS

CLASS ACTION CASE DETAILS: The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA")  had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Kiromic you have until October 4, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Kiromic securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.